New Weight Loss Compound Shows Promise in Mice

Researchers from the University of California, Berkeley, have discovered a compound that led to significant weight loss in obese mice. This study, published in Science Advances, highlights that the compound, TOFA, enhances energy use instead of decreasing appetite.

TOFA’s Effects

The compound reduced mice’s body weight by 18% without altering their food intake or significantly affecting lean mass. Unlike popular weight-loss medications like semaglutide, which can cause side effects and loss of lean mass, TOFA promotes weight reduction by boosting energy expenditure.

“Muscle mass is really important for our function during the day. It helps fight the effects of aging,” said Dr. Leslie Pristas, a bariatric surgeon.

TOFA works internally by blocking enzymes that produce lipids and activating genes involved in fat burning. Treated mice used up to 18% more energy without increased body temperature or decreased activity.

Combination Benefits

When combined with other drugs such as semaglutide or tirzepatide, TOFA improved body weight, blood sugar, insulin, and triglyceride levels more than individual treatments. Mice given TOFA maintained healthy weights after treatment ended, unlike those given semaglutide.

However, Dr. Pristas cautions against thinking any single drug can prevent weight regain. “Obesity is super complex,” she explained. Various factors contribute to weight gain, making it difficult to rely on a single solution.

TOFA and Fatty Liver Disease

TOFA also showed promise for treating metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. In mice, it reduced liver fat, inflammation, and fibrosis without raising blood triglyceride levels.

Study Limitations

The tests were conducted only on male mice. Further research is needed to determine if TOFA is effective in females. Its effects on humans remain unknown, making professional consultation essential before making any medication changes.

“If it sounds too good to be true, it’s probably too good to be true,” Dr. Pristas cautioned.

The study suggests potential benefits from TOFA, either alone or with other therapies. The authors disclosed connections to ReRx Therapeutics, which is exploring development options for TOFA.